Price T Rowe Associates Inc. MD Raises Stock Position in Stryker Co. (NYSE:SYK)

Price T Rowe Associates Inc. MD increased its position in Stryker Co. (NYSE:SYK - Free Report) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,109,722 shares of the medical technology company's stock after acquiring an additional 54,693 shares during the period. Price T Rowe Associates Inc. MD owned approximately 2.91% of Stryker worth $4,000,056,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Stryker in the fourth quarter valued at $25,000. Rakuten Securities Inc. grew its stake in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker during the 4th quarter valued at about $30,000. BankPlus Trust Department acquired a new position in Stryker during the fourth quarter worth about $33,000. Finally, Activest Wealth Management purchased a new stake in shares of Stryker in the fourth quarter valued at about $36,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SYK has been the subject of a number of recent research reports. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research note on Tuesday, March 4th. JPMorgan Chase & Co. boosted their price target on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Stifel Nicolaus upped their price objective on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Finally, Wells Fargo & Company upped their target price on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $423.53.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.

Stryker Price Performance

SYK stock opened at $348.62 on Wednesday. The stock has a 50-day moving average price of $369.25 and a two-hundred day moving average price of $373.06. The company has a market cap of $133.06 billion, a PE ratio of 44.93, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm posted $3.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.96%. Stryker's dividend payout ratio (DPR) is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.